Cytokines News and Research

Latest Cytokines News and Research

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Depressed and suicidal individuals linked to low levels of stress hormone cortisol

Depressed and suicidal individuals have low levels of the stress hormone cortisol in their blood and saliva. They also have substances in their spinal fluid that suggest there is increased inflammation in the brain. These findings could help to develop new methods for diagnosing and treating suicidal patients.

29 Nov 2010

Scientists reveal long-standing mystery about HIV infection

Scientists at Gladstone Institute of Virology and Immunology have solved a long-standing mystery about HIV infection-namely how HIV promotes the death of CD4 T cells.

25 Nov 2010

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

Idera Pharmaceuticals, Inc. announced today that it is presenting preclinical data from a study evaluating the mechanism of action of one of its Toll-like receptor (TLR) 7 and TLR9 antagonist candidates in a model of hyperlipidemia.

18 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Cyplasin Biomedical is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has selected Aurobindo Pharma located in Hyderabad , India to supply the active pharmaceutical ingredient (API) component for its Ribavirin drug product called C-Virin.

15 Nov 2010

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

NanoViricides, Inc. reports that its optimized FluCide™ drug candidates achieved dramatic reduction in viral load within the lungs of animals infected with a lethal dose of H1N1 influenza virus.

15 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

UCB and U.S. based partner Immunomedics Inc. announced that results from the phase IIB study, EMBLEM, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE.

10 Nov 2010

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.

9 Nov 2010

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Genentech, Inc., a member of the Roche Group today announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving ACTEMRA (tocilizumab) experienced a rapid, measured response as early as one week after beginning ACTEMRA, and improvement in disease activity within four weeks.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.

3 Nov 2010

Vitrolife operating income increases 3% to SEK 25 million for January to September 2010

Vitrolife: Growth in local currency was 13 percent. Sales amounted to SEK 217 (207) million, corresponding to an increase of 4 percent in SEK. Operating income before research and development costs increased by 11 percent and amounted to SEK 58 (53) million.

2 Nov 2010

Arthritis drugs also prevent post-operative cognitive decline: Study

Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive problems after surgery, according to a new study by researchers at Imperial College London and University of California, San Francisco (UCSF).

2 Nov 2010

Cytokines News and Research

Latest Cytokines News and Research

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Depressed and suicidal individuals linked to low levels of stress hormone cortisol

Scientists reveal long-standing mystery about HIV infection

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Skin to blood transformation in the lab

Immunomedics product candidates, technologies receive recognition from QTDP program

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Vitrolife operating income increases 3% to SEK 25 million for January to September 2010

Arthritis drugs also prevent post-operative cognitive decline: Study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cytokines News and Research

Latest Cytokines News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in